IP Verse

Preservative Free Brimonidine And Timolol Solutions - EP2598119

The patent EP2598119 was granted to Allergan on Sep 19, 2018. The application was originally filed on Jul 28, 2011 under application number EP11745861A. The patent is currently recorded with a legal status of "Revoked".

EP2598119

ALLERGAN
Application Number
EP11745861A
Filing Date
Jul 28, 2011
Status
Revoked
Jul 3, 2020
Grant Date
Sep 19, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

WACHTERSHAUSER & HARTZ PATENTANWALTSPARTNERSCHAFT MBB BLODIGJun 18, 2019 -
INSTONEJun 4, 2019ADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20100368681-
DESCRIPTIONUS7323463
INTERNATIONAL-SEARCH-REPORTEP2033649
INTERNATIONAL-SEARCH-REPORTUS2003199507
INTERNATIONAL-SEARCH-REPORTUS2006198892
INTERNATIONAL-SEARCH-REPORTWO2008024846
OPPOSITIONUS2003199507
OPPOSITIONWO03088973
OPPOSITIONWO2008024846
OPPOSITIONWO2011087790

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "Brimonidine Tartrate", NICE, (20161114), XP055628977-
OPPOSITION- C. KENT, "Preserving Without Preservatives", Review of Ophthalmology, (20060220), URL: https://www.reviewofophthalmology.com/article/preserving-without-preservatives, (20190602), XP055628983-
OPPOSITION- "Combigan Patient Information", Allergan Pharmaceuticals, (20061020), pages 1 - 5, XP055628987-
OPPOSITION- "EMEA PUBLIC STATEMENT ON ANTIMICROBIAL PRESERVATIVES IN OPHTHALMIC PREPARATIONS FOR HUMAN USE", European Medicines Agency, (20091208), XP055628980-
OPPOSITION- Patient Information Leaflet for Alphagan® with update history-
OPPOSITION- PubChem Compound, (20190511), Database accession no. 54405, URL: https://pubchem.ncbi.nlm.nih.gov/compound/brimonidine_tartrate, XP055628972-
OPPOSITION- R.W. YEE, "The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy", Curr. Opin. Ophthalmology 2007, (20070000), vol. 18, pages 134 - 139, XP055456925-
OPPOSITION- BAUDOIN et al., "Preservatives in eyedrops: The good, the bad and the ugly", Progress in Retinal and Eye Research, (20100700), vol. 29, no. 4, pages 312 - 334, XP055616054
OPPOSITION- A. BAGNIS et al., "Antiglaucoma drugs: The role of preservative-free formulations", Saudi Journal of Ophthalmology, (20110828), vol. 25, no. 4, pages 389 - 394, XP028332801
OPPOSITION- C. BAUDOUIN, "Detrimental effect of preservatives in eyedrops: implications for the treatment of Glaucoma", Acta Ophthalmologica 2008, (20080000), vol. 86, doi:10.1111/j.1755-3768.2008.01250.x, pages 716 - 726, XP055603673
OPPOSITION- M. HOPES et al., "Preservative-free Treatment in Glaucoma is a Sensible and Realistic Aim for the Future", European Ophthalmic Review, (20100813), vol. 4, pages 23 - 28, XP055628982
OPPOSITION- E. MOISSEIEV et al., "Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily", Clinical Ophthalmology, (20130624), vol. 7, pages 1269 - 1273, XP055628989

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents